Phase I open label, clinical trial to evaluate the safety, tolerability and immunogenicity of Chikungunya vaccine in healthy adults of 18 to 50 years age - CHIKV40ug
Latest Information Update: 01 Nov 2020
At a glance
- Drugs Chikungunya virus vaccine (Primary)
- Indications Chikungunya virus infections
- Focus Adverse reactions
- Acronyms CHIKV40ug
- Sponsors Bharat Biotech
- 23 Oct 2020 Status changed from not yet recruiting to completed.
- 29 Jul 2020 New trial record